HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
50:@0.083944:0.033217:0.104640:0.033217:0.104640:0.013052:0.083944:0.013052:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
8.:@0.076190:0.082219:0.085962:0.082219:0.085962:0.069944:0.076190:0.069944:0.006515:0.003257
Bartalena L, Tanda ML. Graves’ Ophthalmopathy. :@0.101390:0.082219:0.396548:0.082219:0.396548:0.069944:0.101390:0.069944:0.006750:0.008032:0.003540:0.003986:0.008032:0.002352:0.007644:0.007173:0.008032:0.004951:0.005433:0.003257:0.004951:0.005009:0.008032:0.007173:0.008055:0.008032:0.004951:0.010807:0.005433:0.003257:0.004939:0.010254:0.003540:0.008032:0.006515:0.007644:0.004563:0.004127:0.004951:0.010219:0.008020:0.007173:0.003986:0.007173:0.008032:0.002352:0.011030:0.007702:0.008020:0.008032:0.003986:0.007173:0.006303:0.003257:0.003257
N Engl J Med.:@0.398241:0.082219:0.480967:0.082219:0.480967:0.069944:0.398241:0.069944:0.008702:0.004951:0.006303:0.007173:0.007914:0.002352:0.004951:0.005668:0.004951:0.010807:0.007644:0.008055:0.003257
2009; 360(10):994-1101.:@0.101390:0.092869:0.231236:0.092869:0.231236:0.080594:0.101390:0.080594:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
9.:@0.076190:0.103519:0.085962:0.103519:0.085962:0.091244:0.076190:0.091244:0.006515:0.003257
Bartalena L, Badeshi L, Dickinson AJ, :@0.101390:0.103519:0.311387:0.103519:0.311387:0.091244:0.101390:0.091244:0.006750:0.008032:0.003540:0.003986:0.008032:0.002352:0.007644:0.007173:0.008032:0.003610:0.005433:0.003257:0.003610:0.006750:0.008032:0.008055:0.007644:0.004563:0.007173:0.002352:0.003610:0.005433:0.003257:0.003610:0.008749:0.002352:0.007608:0.005903:0.002352:0.007173:0.004563:0.007702:0.007173:0.003610:0.008702:0.005668:0.003257:0.003257
et al.:@0.311728:0.103519:0.340609:0.103519:0.340609:0.091244:0.311728:0.091244:0.007644:0.003986:0.003610:0.008032:0.002352:0.003257
 Consensus statement of:@0.340609:0.103519:0.480956:0.103519:0.480956:0.091244:0.340609:0.091244:0.003610:0.009560:0.007702:0.007173:0.004563:0.007644:0.007173:0.004563:0.007150:0.004563:0.003610:0.004563:0.003986:0.008032:0.003986:0.007644:0.011030:0.007644:0.007173:0.003986:0.003598:0.007702:0.003692
the European Group on Graves’ Orbitopathy (EUGOGO) on man-:@0.101390:0.114169:0.480932:0.114169:0.480932:0.101894:0.101390:0.101894:0.003986:0.007173:0.007644:0.003869:0.006303:0.007150:0.003540:0.007702:0.008020:0.007644:0.008032:0.007173:0.003869:0.010254:0.003540:0.007702:0.007150:0.008020:0.003869:0.007702:0.007173:0.003869:0.010254:0.003540:0.008032:0.006515:0.007644:0.004563:0.004127:0.003881:0.010219:0.003540:0.008020:0.002352:0.003986:0.007702:0.008020:0.008032:0.003986:0.007173:0.006303:0.003881:0.004339:0.006303:0.007702:0.010254:0.010219:0.010254:0.010219:0.004339:0.003881:0.007702:0.007173:0.003869:0.011030:0.008032:0.007173:0.003904
agement of Graves’ orbitopathy. :@0.101390:0.125071:0.293983:0.125071:0.293983:0.112796:0.101390:0.112796:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.003257:0.007702:0.003692:0.003257:0.010254:0.003540:0.008032:0.006515:0.007644:0.004563:0.004127:0.003257:0.007702:0.003540:0.008020:0.002352:0.003986:0.007702:0.008020:0.008032:0.003986:0.007173:0.006303:0.003257:0.003257
Thyroid. :@0.293960:0.125071:0.340609:0.125071:0.340609:0.112796:0.293960:0.112796:0.005009:0.007173:0.006303:0.003540:0.007702:0.002352:0.008055:0.003257:0.003257
2008;18:333-346.:@0.340597:0.125071:0.432449:0.125071:0.432449:0.112796:0.340597:0.112796:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
10. Nedrebo BG, Holm pA, Uhlving s, :@0.076179:0.135972:0.293149:0.135972:0.293149:0.123697:0.076179:0.123697:0.006515:0.006515:0.003257:0.008914:0.008702:0.007644:0.008055:0.003540:0.007644:0.008020:0.007702:0.003716:0.006750:0.010254:0.003257:0.003728:0.008032:0.007702:0.002352:0.011030:0.003728:0.006961:0.008702:0.003257:0.003716:0.007702:0.007173:0.002352:0.006515:0.002352:0.007173:0.007914:0.003728:0.005856:0.003257:0.857648
et al.:@0.293619:0.135972:0.322617:0.135972:0.322617:0.123697:0.293619:0.123697:0.007644:0.003986:0.003728:0.008032:0.002352:0.003257
 predictors of outcome and:@0.322617:0.135972:0.480932:0.135972:0.480932:0.123697:0.322617:0.123697:0.003728:0.006961:0.003540:0.007644:0.008055:0.002352:0.007608:0.003986:0.007702:0.003540:0.004563:0.003716:0.007702:0.003692:0.003728:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.003716:0.008032:0.007173:0.008055
comparison of different drug regimens for the prevention of relapse :@0.101379:0.146874:0.484201:0.146874:0.484201:0.134599:0.101379:0.134599:0.007608:0.007702:0.011030:0.008020:0.008032:0.003540:0.002352:0.004563:0.007702:0.007173:0.002834:0.007702:0.003692:0.002834:0.008055:0.002352:0.003692:0.003692:0.007644:0.003540:0.007644:0.007173:0.003986:0.002822:0.008055:0.003540:0.007150:0.007914:0.002834:0.003540:0.007644:0.007914:0.002352:0.011030:0.007644:0.007173:0.004563:0.002834:0.003692:0.007702:0.003540:0.002834:0.003986:0.007173:0.007644:0.002834:0.008020:0.003540:0.007644:0.006515:0.007644:0.007173:0.003986:0.002352:0.007702:0.007173:0.002822:0.007702:0.003692:0.002834:0.003540:0.007644:0.002352:0.008032:0.008020:0.004563:0.007644:0.003257
in patients with Graves’ disease. :@0.101379:0.157775:0.287010:0.157775:0.287010:0.145500:0.101379:0.145500:0.002352:0.007173:0.003257:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003257:0.009772:0.002352:0.003986:0.007173:0.003257:0.010254:0.003540:0.008032:0.006515:0.007644:0.004563:0.004127:0.003257:0.008055:0.002352:0.004563:0.007644:0.008032:0.004563:0.007644:0.003257:0.003257
Eur J Endocrinol.:@0.287010:0.157775:0.379403:0.157775:0.379403:0.145500:0.287010:0.145500:0.006303:0.007150:0.003540:0.003257:0.005668:0.003257:0.006303:0.007173:0.008055:0.007702:0.007608:0.003540:0.002352:0.007173:0.007702:0.002352:0.003257
 2002;147:583-9.:@0.379391:0.157775:0.467985:0.157775:0.467985:0.145500:0.379391:0.145500:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.003257
11. Cooper Ds. Antithyroid drugs. :@0.076179:0.168677:0.272241:0.168677:0.272241:0.156401:0.076179:0.156401:0.006515:0.006515:0.003257:0.008914:0.009560:0.007702:0.007702:0.008020:0.007644:0.003540:0.003257:0.008749:0.005856:0.003257:0.003257:0.008702:0.007173:0.003986:0.002352:0.003986:0.007173:0.006303:0.003540:0.007702:0.002352:0.008055:0.003257:0.008055:0.003540:0.007150:0.007914:0.004563:0.003257:0.835729
N Engl J Med.:@0.272217:0.168677:0.349863:0.168677:0.349863:0.156401:0.272217:0.156401:0.008702:0.003257:0.006303:0.007173:0.007914:0.002352:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055:0.003257
 2005;352 (9):905-914.:@0.349852:0.168677:0.469925:0.168677:0.469925:0.156401:0.349852:0.156401:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
12. Wartofsky L, Glinoer D, solomon B, :@0.076179:0.179578:0.305884:0.179578:0.305884:0.167303:0.076179:0.167303:0.006515:0.006515:0.003257:0.008914:0.011289:0.008032:0.003540:0.003986:0.007702:0.003692:0.004563:0.005903:0.006303:0.004998:0.005433:0.003257:0.004998:0.010254:0.002352:0.002352:0.007173:0.007702:0.007644:0.003540:0.004998:0.008749:0.003257:0.005009:0.005856:0.007702:0.002352:0.007702:0.011030:0.007702:0.007173:0.004998:0.006750:0.003257:0.003257
et al.:@0.307624:0.179578:0.337893:0.179578:0.337893:0.167303:0.307624:0.167303:0.007644:0.003986:0.004998:0.008032:0.002352:0.003257
 Differences and similari-:@0.337893:0.179578:0.480944:0.179578:0.480944:0.167303:0.337893:0.167303:0.004998:0.008749:0.002352:0.003692:0.003692:0.007644:0.003540:0.007644:0.007173:0.007608:0.007644:0.004563:0.004998:0.008032:0.007173:0.008055:0.004998:0.004563:0.002352:0.011030:0.002352:0.002352:0.008032:0.003540:0.002375:0.003904
ties in the diagnosis and treatment of Graves’ disease in Europe,:@0.101379:0.190480:0.480944:0.190480:0.480944:0.178204:0.101379:0.178204:0.003986:0.002352:0.007644:0.004563:0.004762:0.002352:0.007173:0.004762:0.003986:0.007173:0.007644:0.004762:0.008055:0.002352:0.008032:0.007914:0.007173:0.007702:0.004563:0.002352:0.004563:0.004774:0.008032:0.007173:0.008055:0.004762:0.003986:0.003540:0.007644:0.008032:0.003986:0.011030:0.007644:0.007173:0.003986:0.004751:0.007702:0.003692:0.004762:0.010254:0.003540:0.008032:0.006515:0.007644:0.004563:0.004127:0.004774:0.008055:0.002352:0.004563:0.007644:0.008032:0.004563:0.007644:0.004774:0.002352:0.007173:0.004762:0.006303:0.007150:0.003540:0.007702:0.008020:0.007644:0.003257
Japan, and the United states. :@0.101379:0.201381:0.274146:0.201381:0.274146:0.189106:0.101379:0.189106:0.005668:0.008032:0.008020:0.008032:0.007173:0.003257:0.003257:0.008032:0.007173:0.008055:0.003257:0.003986:0.007173:0.007644:0.003257:0.007702:0.007173:0.002352:0.003986:0.007644:0.008055:0.003257:0.005856:0.003986:0.008032:0.003986:0.007644:0.004563:0.003257:0.790997
Thyroid.:@0.274122:0.201381:0.317514:0.201381:0.317514:0.189106:0.274122:0.189106:0.005009:0.007173:0.006303:0.003540:0.007702:0.002352:0.008055:0.003257
 1991;1:129-35.:@0.317502:0.201381:0.399582:0.201381:0.399582:0.189106:0.317502:0.189106:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
13. Toft AD. subclinical hyperthyroidism. :@0.076167:0.212283:0.309306:0.212283:0.309306:0.200007:0.076167:0.200007:0.006515:0.006515:0.003257:0.008914:0.005009:0.007702:0.003692:0.003986:0.003234:0.008702:0.008749:0.003257:0.003246:0.005856:0.007150:0.008020:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.003257:0.007173:0.006303:0.008020:0.007644:0.003540:0.003986:0.007173:0.006303:0.003540:0.007702:0.002352:0.008055:0.002352:0.004563:0.011030:0.003257:0.003257
N Engl J Med.:@0.309294:0.212283:0.386905:0.212283:0.386905:0.200007:0.309294:0.200007:0.008702:0.003246:0.006303:0.007173:0.007914:0.002352:0.003246:0.005668:0.003246:0.010807:0.007644:0.008055:0.003257
 2001;345(7):512-:@0.386905:0.212283:0.480909:0.212283:0.480909:0.200007:0.386905:0.200007:0.003246:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904
516.:@0.101367:0.223184:0.124168:0.223184:0.124168:0.210909:0.101367:0.210909:0.006515:0.006515:0.006515:0.003257
14. Ross sD. subclinical hyperthyroidism. Available at www.uptodate-:@0.076167:0.234086:0.480944:0.234086:0.480944:0.221810:0.076167:0.221810:0.006515:0.006515:0.003257:0.008914:0.007138:0.007702:0.004563:0.004563:0.004469:0.005856:0.008749:0.003257:0.004469:0.005856:0.007150:0.008020:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.004480:0.007173:0.006303:0.008020:0.007644:0.003540:0.003986:0.007173:0.006303:0.003540:0.007702:0.002352:0.008055:0.002352:0.004563:0.011030:0.003257:0.004469:0.008702:0.006515:0.008032:0.002352:0.002352:0.008032:0.008020:0.002352:0.007644:0.004480:0.008032:0.003986:0.004469:0.009772:0.009772:0.009772:0.003257:0.007150:0.008020:0.003986:0.007702:0.008055:0.008032:0.003986:0.007644:0.542018
online.com. Accessed March 2012. :@0.101367:0.244987:0.304496:0.244987:0.304496:0.232712:0.101367:0.232712:0.007702:0.007173:0.002352:0.002352:0.007173:0.007644:0.003257:0.007608:0.007702:0.011018:0.003257:0.003257:0.008702:0.007608:0.007608:0.007644:0.004563:0.004563:0.007644:0.008055:0.003257:0.010807:0.008032:0.003540:0.007608:0.007173:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257
15.  surks MI, Ortiz E, Daniels GH, :@0.076167:0.255889:0.260364:0.255889:0.260364:0.243613:0.076167:0.243613:0.006515:0.006515:0.003257:0.003257:0.005656:0.005856:0.007150:0.003540:0.005903:0.004563:0.002987:0.010807:0.002658:0.003257:0.002987:0.010219:0.003540:0.003986:0.002352:0.004998:0.002987:0.006303:0.003257:0.002987:0.008749:0.008032:0.007173:0.002352:0.007644:0.002352:0.004563:0.002999:0.010254:0.008032:0.003257:0.733400
et al.:@0.260093:0.255889:0.288351:0.255889:0.288351:0.243613:0.260093:0.243613:0.007644:0.003986:0.002987:0.008032:0.002352:0.003257
 subclinical thyroid disease. scien-:@0.288351:0.255889:0.480920:0.255889:0.480920:0.243613:0.288351:0.243613:0.002987:0.005856:0.007150:0.008020:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.002999:0.003986:0.007173:0.006303:0.003540:0.007702:0.002352:0.008055:0.002987:0.008055:0.002352:0.004563:0.007644:0.008032:0.004563:0.007644:0.003257:0.002987:0.005856:0.007608:0.002352:0.007644:0.007173:0.003904
tific review and guidelines for diagnosis and management. :@0.101367:0.266790:0.443185:0.266790:0.443185:0.254515:0.101367:0.254515:0.003986:0.002352:0.002863:0.002863:0.007608:0.003881:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.003881:0.008032:0.007173:0.008055:0.003881:0.007914:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004563:0.003881:0.003692:0.007702:0.003540:0.003869:0.008055:0.002352:0.008032:0.007914:0.007173:0.007702:0.004563:0.002352:0.004563:0.003881:0.008032:0.007173:0.008055:0.003881:0.011030:0.008032:0.007173:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.003257:0.003257
JAMA.:@0.443808:0.266790:0.480944:0.266790:0.480944:0.254515:0.443808:0.254515:0.005668:0.008702:0.010807:0.008702:0.003257
 :@0.480932:0.266790:0.484189:0.266790:0.484189:0.254515:0.480932:0.254515:0.003257
2004;291(2):228 -238.:@0.101367:0.277692:0.218183:0.277692:0.218183:0.265416:0.101367:0.265416:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003257:0.003904:0.006515:0.006515:0.006515:0.003257
16. Nayak B, Burnman K. Thyroid toxicosis and thyroid storm. :@0.076167:0.288593:0.421066:0.288593:0.421066:0.276318:0.076167:0.276318:0.006515:0.006515:0.003257:0.008914:0.008702:0.008032:0.006303:0.008032:0.005903:0.003175:0.006750:0.003257:0.003175:0.006750:0.007150:0.003540:0.007173:0.011030:0.008032:0.007173:0.003163:0.006950:0.003257:0.003163:0.005009:0.007173:0.006303:0.003540:0.007702:0.002352:0.008055:0.003163:0.003986:0.007702:0.005644:0.002352:0.007608:0.007702:0.004563:0.002352:0.004563:0.003175:0.008032:0.007173:0.008055:0.003175:0.003986:0.007173:0.006303:0.003540:0.007702:0.002352:0.008055:0.003163:0.004563:0.003986:0.007702:0.003540:0.011030:0.003257:0.529871
Endocrinol :@0.420972:0.288593:0.484189:0.288593:0.484189:0.276318:0.420972:0.276318:0.006303:0.007173:0.008055:0.007702:0.007608:0.003540:0.002352:0.007173:0.007702:0.002352:0.003257
Metab Clin North Am. :@0.101367:0.299494:0.228414:0.299494:0.228414:0.287219:0.101367:0.287219:0.010807:0.007644:0.003986:0.008032:0.008020:0.003257:0.009560:0.002352:0.002352:0.007173:0.003257:0.008702:0.007702:0.003540:0.003986:0.007173:0.003257:0.008702:0.011030:0.003257:0.003257
2006;35:663-686. :@0.228390:0.299494:0.323499:0.299494:0.323499:0.287219:0.228390:0.287219:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257:0.003257
17. Ross sD. Thyroid storm. Available at www.uptodateonline.com. Ac-:@0.076167:0.310396:0.480920:0.310396:0.480920:0.298121:0.076167:0.298121:0.006515:0.006515:0.003257:0.008914:0.007138:0.007702:0.004563:0.004563:0.003269:0.005856:0.008749:0.003257:0.003269:0.005009:0.007173:0.006303:0.003540:0.007702:0.002352:0.008055:0.003269:0.004563:0.003986:0.007702:0.003540:0.011030:0.003257:0.003269:0.008702:0.006515:0.008032:0.002352:0.002352:0.008032:0.008020:0.002352:0.007644:0.003281:0.008032:0.003986:0.003269:0.009772:0.009772:0.009772:0.003257:0.007150:0.008020:0.003986:0.007702:0.008055:0.008032:0.003986:0.007644:0.007702:0.007173:0.002352:0.002352:0.007173:0.007644:0.003257:0.007608:0.007702:0.011018:0.003257:0.003269:0.008702:0.007608:0.442112
cessed March 2012.:@0.101355:0.321297:0.214420:0.321297:0.214420:0.309022:0.101355:0.309022:0.007608:0.007644:0.004563:0.004563:0.007644:0.008055:0.003257:0.010807:0.008032:0.003540:0.007608:0.007173:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257